Grant of U.S. Patent for OptiMAL

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, is pleased to announce that the Company's patent application no. 17/287,441 (the "Patent") has been granted by the United States Patent and Trademark Office (the "U.S. Patent Office"). The grant of the Patent follows the receipt of a notice of allowance in respect of the Patent from the U.S. Patent Office, details of which were announced by the Company on 22 May 2025.

To view the supporting video by CEO Adrian Kinkaid and ask questions, please go to the Fusion investor hub: https://investorhub.fusionantibodies.com/link/8r6bdr

The Patent entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL® platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.

The Company is also progressing patent applications in respect of the OptiMAL® Library in several other territories worldwide including Europe, China and Japan.

Having secured the US patent, the Company is now targeting a scientific presentation at the Antibody Engineering and Therapeutics conference in San Diego in December 2025 and working toward a commercial launch of OptiMAL® at this event.

Richard Buick, CSO of Fusion, said: "I am really pleased that the U.S. Patent Office has granted the OptiMAL® Library patent application. This confirms our unique approach to antibody library design and protects Fusion's OptiMAL® antibody library for years to come."

Adrian Kinkaid, CEO of Fusion, said: "This good news arrives at an almost perfect point in time as we confirm the desired binding properties of antibodies discovered using OptiMAL® and as we prepare for the formal commercial launch of the service."